Workflow
uniQure的主要药物候选产品(用于治疗亨廷顿舞蹈病)
icon
Search documents
ROSEN, A TRUSTED AND LEADING INVESTOR RIGHTS FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE
Globenewswire· 2026-03-29 02:35
Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the April 13, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought shares during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 13, 2026, to serve as lead plaintiff [2] - The lawsuit claims that uniQure misrepresented and/or failed to disclose critical information regarding its Pivotal Study and Biologics License Application (BLA) timeline [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3]